Under construction – not a live service
Sign in
Taking people in ChinaPhase 3

Tests HMPL-760 with R-GemOx in relapsed or refractory large B-cell lymphoma

Tests HMPL-760 plus R-GemOx against placebo plus R-GemOx in adults with returned lymphoma.

Plain-language title generated from the registry record
Registry title: A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

Key facts

Where
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fujian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Tangshan, Tianjin, Ürümqi, Wenzhou, Wuhan, Xi'an, Xi’an, Xiamen, Xuzhou, and Zhengzhou, ChinaSee the 51 sites
Phase
Phase 3

Where in China

  • Baoding NO.1 Central HospitalBaoding, ChinaTaking people
  • Beijing GoBroad HospitalBeijing, ChinaTaking people
  • Beijing Tongren Hospital, Capital Medical UniversityBeijing, ChinaTaking people
  • The First Affiliated Hospital of Bengbu Medical CollegeBengbu, ChinaTaking people
  • The First Hospital of Jilin UniversityChangchun, ChinaTaking people
  • Hunan Cancer HospitalChangsha, ChinaTaking people
  • People's Hospital of Hunan ProvinceChangsha, ChinaTaking people
  • The Second Xiangya Hospital of Central South UniversityChangsha, ChinaTaking people
  • Sichuan Provincial People's HospitalChengdu, ChinaTaking people
  • West China Hospital of Sichuan UniversityChengdu, ChinaTaking people
  • Chongqing University Cancer HospitalChongqing, ChinaTaking people
  • The First Affiliated Hospital of Chongqing Medical UniversityChongqing, ChinaTaking people
  • Quanzhou First Hospital.FujianFujian, ChinaTaking people
  • Fujian Medical University Union HospitalFuzhou, ChinaTaking people
  • Guangdong Provincial People's HospitalGuangzhou, ChinaTaking people
  • Sun Yat-sen University Cancer CenterGuangzhou, ChinaTaking people
  • ZhuJiang Hospital of Southern Medical University（The Second Clinical Medical College）Guangzhou, ChinaTaking people
  • The Affiliated Hospital of Guizhou Medical UniversityGuiyang, ChinaTaking people
  • The First Affiliated Hospital, Zhejiang UniversityHangzhou, ChinaTaking people
  • Zhejiang Cancer HospitalHangzhou, ChinaTaking people
  • Harbin Medical University Cancer HospitalHarbin, ChinaTaking people
  • The Second Affiliated Hospital Of Anhui Medical UniversityHefei, ChinaTaking people
  • Qilu Hospital of Shandong UniversityJinan, ChinaTaking people
  • Shandong Cancer Hospital & instituteJinan, ChinaTaking people
  • The First Affiliated Hospital of Kunming Medical UniversityKunming, ChinaNot yet recruiting
  • Jiangxi Cancer HospitalNanchang, ChinaTaking people
  • Jiangsu Cancer HospitalNanjing, ChinaTaking people
  • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical SchoolNanjing, ChinaTaking people
  • The First Affiliated Hospital of Guangxi Medical UniversityNanning, ChinaTaking people
  • The Affiliated Hospital of Qingdao UniversityQingdao, ChinaTaking people
  • Fudan University Shanghai Cancer CenterShanghai, ChinaTaking people
  • Ruijin Hospital Shanghai Jiaotong University School of MedicineShanghai, ChinaTaking people
  • Tong Ren Hospital,Shanghai Jiao Tong University School Of MedicineShanghai, ChinaNot yet recruiting
  • Tongji Hospital of Tongji UniversityShanghai, ChinaTaking people
  • Shengjing Hospital Of China Medical UniversityShenyang, ChinaTaking people
  • Shenzhen People's HospitalShenzhen, ChinaTaking people
  • Shanxi Provincial Cancer HospitalTaiyuan, ChinaTaking people
  • North China University of Science and Technology Affiliated HospitalTangshan, ChinaTaking people
  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeTianjin, ChinaTaking people
  • Tianjin Medical University Cancer Institute & HospitalTianjin, ChinaTaking people
  • Tianjin People's HospitalTianjin, ChinaTaking people
  • People's Hospital of Xinjiang Uygur Autonomous RegionÜrümqi, ChinaTaking people
  • The First Affiliated Hospital of WMUWenzhou, ChinaTaking people
  • Hubei Cancer HospitalWuhan, ChinaTaking people
  • Wuhan Union Hospital of ChinaWuhan, ChinaTaking people
  • The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hosiptal)Xi'an, ChinaTaking people
  • The First Affiliated Hospital of Xi'an Jiaotong UniversityXi’an, ChinaTaking people
  • The First Affiliated hospital of Xiamen UniversityXiamen, ChinaNot yet recruiting
  • The affiliated hospital of xuzhou medical universityXuzhou, ChinaTaking people
  • Henan Cancer HospitalZhengzhou, ChinaTaking people
  • The First Affiliated Hospital of Zhengzhou UniversityZhengzhou, ChinaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Hutchmed
Trial code
NCT07409428
Record updated
10 November 2026
Original description
This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R/R DLBCL.Read full original descriptionShow less

A Phase III Randomized, Double-Blind, Positive Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R/R DLBCL.

Inclusion: Sign the ICF and be able to follow the requirements of study protocol; Age ≥18 years; ECOG performance status score between 0 and 2; Histopathologically confirmed diagnosis of DLBCL; The investigator judges that the patient's current condition requires further treatment; Patients should have at least one bi-dimensionally measurable lesion; Expected survival is more than 12 weeks.

Exclusion: History of significant organ bleeding, including gastrointestinal bleeding, hematencephalon, haemoptysis, etc., within 8 weeks prior to the first dose of study drug; Known risk of bleeding, such as coagulation factor deficiency, vascular hemophilia; or the patient is receiving vitamin K antagonist (warfarin); The toxic reactions of previous anti-tumor therapy have not recovered to the level of ≤ grade 1 (except for alopecia and decreased appetite and other conditions that have been clearly required in the inclusion and exclusion criteria); Organ insufficiency; Currently known history of liver disease, including cirrhosis, alcoholic liver, known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV); Clinically significant active infection; Patients with known primary or secondary central nervous system lymphoma (CNSL) or the presence of clinical symptoms suggestive of CNSL; Women who are pregnant (positive pregnancy test during the screening period) or breastfeeding.

ClinicalTrials.gov NCT07409428